👋 After the long pandemic, last week we could finally make it to Iceland to meet our colleagues at EpiEndo Pharmaceuticals face-to-face.The occasion was EPIColiX – a joint ground-breaking project aiming at developing a new gut-on-chip model for drug testing under the Eurostars program. ⚡️ We are very pleased about the achievements obtained so far in this…

🎉 Let’s start 2023 with good news: The FDA Modernization Act 2.0 has passed congress and is inked by President Biden! 🧫 This big achievement lets the FDA consider non-animal cutting-edge testing methods as standalone tests for preclinical studies, finally allowing the use Organs-on-Chip and NAMs for drug safety and efficacy assessment. 📑 𝘛𝘩𝘦 𝘍𝘋𝘈 𝘔𝘰𝘥𝘦𝘳𝘯𝘪𝘻𝘢𝘵𝘪𝘰𝘯 𝘈𝘤𝘵 2.0 𝘱𝘳𝘰𝘮𝘪𝘴𝘦𝘴 𝘵𝘰 𝘳𝘦𝘣𝘰𝘰𝘵 𝘢 𝘣𝘳𝘰𝘬𝘦𝘯 𝘥𝘳𝘶𝘨…

🏆 Congratulations to Aude Rapet for receiving the ecopa Award at the European Society of Toxicology in Vitro ESTIV Congress!!! We kindly thank the awarding committee, Costanza Rovida and Stefano Lorenzetti, for the recognition of this work, in which Aude presented the AXbreathing lung-on-chip use case in toxicology and drug testing with a focus on 3R and regulatory submission.   🙏 Thank you to…

⭐️ Did you miss the EUSAAT congress last month?  👀 If you did, here is your chance to catch up! Check out this insightful summary of the latest technologies and research to replace animals shown during the congress.   🙏 Thanks Menschen Für Tierrechte for the highlight.  

📢 As of Sept 29, the FDA Modernization Act 2.0 has passed the US Senate.   💡This bill marks a turning point in how animal testing is seen in drug development.  By stating that innovative technologies such as Organs-on-Chip and microphysiological systems can be used to evaluate drug safety and efficacy, the bill enables relevant validated human models to replace…

🤔 Since 1938, the FDA has required that all drugs need to be tested in animal models prior to clinical trials. However, science and technology have advanced considerably in the past years. So, it is time to change!  💪 At AlveoliX we support the initiative of the FDA Modernization Act to recognize and implement legally the use of alternatives…

📢 Find out who is in the running for the 2022 Lush Prize! 🏅 We are very excited to have made it to the Shortlist among many great applicants with our project “A barrier-on-chip with integrated 3D stretching: an alternative predictive tool to support decision making”. 🤞 Let’s keep our fingers crossed! See you at the…

🏆 We made it! We are the winner of the Swiss Medtech Award 2022 🙏 A big thank you to the AlveoliX team for their commitment and to all the people who support us.– ARTORG Center for Biomedical Engineering Research– Insel Gruppe– Innosuisse– Bern Economic Development Agency 👏🏼 Thank you to the jury for choosing AlveoliX and to the…

🌐 CSL Behring, Insel Gruppe and AlveoliX have joined forces within sitem-insel AG’s hub to improve translation and find new treatments for lung diseases.  🔬 Discover how this close collaboration works for the benefit of patients. 📰  Learn more about this cooperation success story in this article by Jasmin Joller (available in EN, DE, FR).